PHILADELPHIA— Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School of Medicine and the Wharton School at the University of Pennsylvania can analyze kidney disease at the cellular level to match the most effective treatments and speed up solutions. This breakthrough, published this week in Nature Genetics, could impact millions who have kidney disease.
“We are moving from guesswork to precision,” said Katalin Susztak, MD, PhD, a professor of Nephrology, Genetics and director of the Penn/CHOP Kidney Innovation Center. “Kidney diseases are not all the same, but the use of AI helped us identify and catalog 70 distinct kinds of kidney cells that appear across human and animal samples. This improves the reliability of research and can lead to potential treatments,” Susztak added.
AI Tools Transform Kidney Disease Care
The Penn team tackled a major challenge in single-cell RNA sequencing, a cutting-edge technique that examines the genetic activity of individual cells. Until now, this method has been difficult to apply to individual patients due to inconsistent cell type definition and uncertainty about which lab models (like mice or rats) best match human diseases.
The team’s solution includes SISKA 1.0 Atlas: A massive dataset built from over 1 million cells across 140 human, mouse, and rat kidney samples. In combination with a new statistical method that examines gene programs—sets of co-regulated genes representing biological pathways—rather than individual genes, it was easier to spot disease-related problems in a person’s cells. The new, open source tool, called CellSpectra, was created right at Penn.
“We built CellSpectra to do what current methods cannot: analyze one patient’s sample at a time, and interpret it in the context of species, disease, and therapy,” said Nancy Zhang, PhD, the Ge Li and Ning Zhao professor of statistics and data science at the Wharton School. “Both of these tools will be free for anyone to use. Now researchers, scientists, and clinicians will all have access to these tools that allow personalized treatments with greater precision,” Susztak added.
Beyond RNA: A New Protein Catalog and Disease Trait Map
In a separate study, the Susztak team has also created the first comprehensive catalog of kidney proteins, offering a new lens on how protein abundance, not just gene expression, contributes to disease. This work, published in Nature Medicine, found that protein levels in kidney cells often don’t match gene activity (a mismatch called discordance), showing that studying genes alone isn’t enough to understand how diseases develop.
“This is a significant step forward in understanding the biology of kidney disease—not just at the RNA level, but also at the functional protein level,” said Susztak. “Linking protein profiles with traits like blood pressure, lipid levels, and kidney function opens new doors for therapies that target the right molecules in the right patients.”
The studies were supported by the National Institutes of Health (2R01DK076077-15, 5R01DK087635-15, 5P50DK114786-07, 5R01DK105821-08, 5R01DK132630-02, R01 DK105821, R01 DK087635, R01 DK076077, R01 DK12345 and 1R56AG081351), the National Science Foundation DMS/NIGMS (2245575), and the Translation Genetics in Renal Medicine (TIGER) grant from the University of Pennsylvania.
###
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System (UPHS) and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $580 million awarded in the 2023 fiscal year. Home to a proud history of “firsts,” Penn Medicine teams have pioneered discoveries that have shaped modern medicine, including CAR T cell therapy for cancer and the Nobel Prize-winning mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System cares for patients in facilities and their homes stretching from the Susquehanna River in Pennsylvania to the New Jersey shore. UPHS facilities include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Doylestown Health, Lancaster General Health, Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, chartered in 1751. Additional facilities and enterprises include Penn Medicine at Home, GSPP Rehabilitation, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.9 billion enterprise powered by nearly 49,000 talented faculty and staff.
Journal
Nature Genetics